Bioequivalence of 1 Soft Gelatine Capsule Containing 200 mg Nintedanib Compared to 2 Soft Gelatine Capsules Containing 100 mg Nintedanib Following Oral Administration in Healthy Male Subjects

Trial Profile

Bioequivalence of 1 Soft Gelatine Capsule Containing 200 mg Nintedanib Compared to 2 Soft Gelatine Capsules Containing 100 mg Nintedanib Following Oral Administration in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Bladder cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Idiopathic pulmonary fibrosis; Liver cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 16 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Oct 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top